NEW YORK, NY / ACCESS Newswire / March 15, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results